BCL-2 and γ-H2AX immunostaining profile in urothelial bladder cancer prognosis

IF 2.9 4区医学 Q2 PATHOLOGY

Pathology, research and practice Pub Date : 2024-10-26 DOI:10.1016/j.prp.2024.155680

Julia Ayumi Ikeda Kawasaki , Lais Capelasso Lucas Pinheiro , Isabely Mayara da Silva , Carlos Alberto Miqueloto , Karen Brajão de Oliveira , Diego Luís Ribeiro , Alda Fiorina Maria Losi Guembarovski , Fernando Terziotti , Wilner Martinez-López , Juliana Mara Serpeloni , Roberta Losi Guembarovski

{"title":"BCL-2 and γ-H2AX immunostaining profile in urothelial bladder cancer prognosis","authors":"Julia Ayumi Ikeda Kawasaki , Lais Capelasso Lucas Pinheiro , Isabely Mayara da Silva , Carlos Alberto Miqueloto , Karen Brajão de Oliveira , Diego Luís Ribeiro , Alda Fiorina Maria Losi Guembarovski , Fernando Terziotti , Wilner Martinez-López , Juliana Mara Serpeloni , Roberta Losi Guembarovski","doi":"10.1016/j.prp.2024.155680","DOIUrl":null,"url":null,"abstract":"<div><div>Urothelial bladder carcinoma (UBC) is a malignant neoplasm of the urinary tract that is highly prevalent worldwide and has a high rate of tumor recurrence. It is known that the <em>BCL2 apoptosis regulator (BCL-2)</em> gene encodes a mitochondrial protein that regulates programmed death cells by apoptosis. In contrast, the <em>H2A.X histone variant</em> (<em>H2AX)</em> gene encodes a histone responsible for regulating and signaling genomic instability processes. The present study aimed to analyze the immunostaining profiles of BCL-2 and γ-H2AX proteins in tissue samples (n=80) from UBC patients (muscle-invasive MI; and non-muscle invasive NMI) using indirect immunohistochemistry and to correlate the results with prognostic and clinical parameters. BCL-2 protein expression was cytoplasmic and absent in half of the samples, including the MI and NMI groups. Strong nuclear expression was observed for γ-H2AX, predominant in the MI samples. The immunostaining profile of both proteins was not associated with tumor recurrence or invasion, and no significant associations were found in relation to prognosis (tumor grade, pathological staging). No significant correlation was found between protein profiles in malignant tissue. All in all, BCL-2 and γ-H2AX did not prove to be candidate markers for UBC clinical management in the present sample, despite their expression in malignant bladder tissue.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033824005910","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Urothelial bladder carcinoma (UBC) is a malignant neoplasm of the urinary tract that is highly prevalent worldwide and has a high rate of tumor recurrence. It is known that the BCL2 apoptosis regulator (BCL-2) gene encodes a mitochondrial protein that regulates programmed death cells by apoptosis. In contrast, the H2A.X histone variant (H2AX) gene encodes a histone responsible for regulating and signaling genomic instability processes. The present study aimed to analyze the immunostaining profiles of BCL-2 and γ-H2AX proteins in tissue samples (n=80) from UBC patients (muscle-invasive MI; and non-muscle invasive NMI) using indirect immunohistochemistry and to correlate the results with prognostic and clinical parameters. BCL-2 protein expression was cytoplasmic and absent in half of the samples, including the MI and NMI groups. Strong nuclear expression was observed for γ-H2AX, predominant in the MI samples. The immunostaining profile of both proteins was not associated with tumor recurrence or invasion, and no significant associations were found in relation to prognosis (tumor grade, pathological staging). No significant correlation was found between protein profiles in malignant tissue. All in all, BCL-2 and γ-H2AX did not prove to be candidate markers for UBC clinical management in the present sample, despite their expression in malignant bladder tissue.

查看原文本刊更多论文

尿路膀胱癌预后中的 BCL-2 和 γ-H2AX 免疫染色图谱

尿路上皮性膀胱癌（UBC）是一种泌尿系统恶性肿瘤，在全球范围内发病率很高，而且肿瘤复发率也很高。众所周知，BCL2 细胞凋亡调节因子（BCL-2）基因编码一种线粒体蛋白，通过细胞凋亡调节程序性死亡细胞。相比之下，H2A.X组蛋白变体（H2AX）基因编码的组蛋白负责调节基因组不稳定过程并发出信号。本研究旨在使用间接免疫组化方法分析 UBC 患者（肌肉浸润性 MI 和非肌肉浸润性 NMI）组织样本（n=80）中 BCL-2 和 γ-H2AX 蛋白的免疫染色谱，并将结果与预后和临床参数相关联。半数样本（包括 MI 和 NMI 组）的 BCL-2 蛋白呈细胞质表达且缺失。γ-H2AX的核表达较强，主要出现在MI样本中。这两种蛋白的免疫染色与肿瘤复发或侵袭无关，与预后（肿瘤分级、病理分期）也无明显关联。恶性肿瘤组织中的蛋白图谱之间也没有发现明显的相关性。总而言之，尽管BCL-2和γ-H2AX在恶性膀胱组织中也有表达，但在本样本中并未证明它们是UBC临床管理的候选标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.